Cyclacel Pharmaceuticals Reports Fourth Quarter and Full Year 2013 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/11/2026
- S&P 500 ends higher as strong inflation data cements rate-hike bets
- Oracle raises full year profit guidance, stock rises after hours
- Oil falls but head for 8% weekly gain on tight supply; US diesel hits record
- 'No panic anywhere' may be the problem, BofA strategists warn
- Buy Shopify stock at this ’AI-enabled entry point,’ analyst says
- After-Hours Movers: ORCL, CRWV, ADBE, ACVA, CPRT, ZUMZ, PMTS, RH
- After-Hours Movers: COO, AEO, NAVN, AVAV, TORO
- After-Hours Movers: LULU, IOT, PATH, DOCU, ASAN, GWRE, ZS, PL, SWBI, OXM
- After-Hours Movers: AVGO, SNOW, HPE, NTAP, NTSK, CHPT, FIVE, TLYS, PVH, RARE
- After-Hours Movers: DELL, PANW, GTLB, CRDO, MDB, HPE, SMCI
Cyclacel Pharmaceuticals, Inc. (CYCC) Posts Q4 Loss of 19c/Share
March 25, 2014 4:05 PM EDTCyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC) reported Q4 EPS of ($0.19), $0.14 better than the analyst estimate of ($0.33). Revenue for the quarter came in at $299 thousand versus the consensus estimate of $90 thousand.
For earnings history and earnings-related data on Cyclacel Pharmaceuticals, Inc. (CYCC) click here.... More
